BRAF V600E mutant mCRC
Up to 12% of patients with mCRC have BRAF mutations1-3
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommends that all patients with mCRC have their tumor tissue genotyped for BRAF mutations at diagnosis.9,10
- NCCN Guidelines® recommends that all patients with mCRC have tumor tissue genotyping for RAS (KRAS and NRAS) and BRAF mutations, individually or as part of an NGS panel
- Testing for KRAS, NRAS, and BRAF mutations should be performed only in laboratories that are certified under the CLIA-88 as qualified to perform high-complexity clinical laboratory (molecular pathology) testing
- NCCN Guidelines also recommends universal MMR or MSI testing, which may be done by a PCR, a validated NGS panel, or via IHC, in newly diagnosed patients with colon or rectal cancer
- Testing for MMR or MSI should be performed only in CLIA-approved laboratories
NCCN makes no representations or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
How do you evaluate BRAF V600E MT mCRC?'
ERBITUX is indicated, in combination with encorafenib, for the treatment of adult patients with mCRC with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy